-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0725, an antibody targeting CD122 developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration and is intended to be used to treat autoimmune diseases.

Zhitongcaijing·11/10/2026 12:09:37
Listen to the news
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0725, an antibody targeting CD122 developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration and is intended to be used to treat autoimmune diseases.